Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages
|
|
- Ralf Powell
- 6 years ago
- Views:
Transcription
1 Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages
2 Introduction It is well accepted that the limitations of antibodies present valuable commercial opportunities for alternative technologies The landscape is complex but is simplified when you consider which alternatives actually work well in the real-world This document discusses the different antibody alternative technologies and sets out why the Company believes Affimers are competitive or differentiated in this landscape Most technologies have some merits and it is therefore difficult to make general statements but without some generalisation the level of detail required would be immense This document provides technical detail in places for those who need it, but the Key Messages slides provide the high level summary 2
3 The Competitive Landscape Human or humanised antibodies and fragments thereof are the dominant binding protein platform. A number of alternative protein binding technologies, or protein scaffolds have been developed in academia. Many have not proven useful in real-world applications but some have established themselves. fab ScFv dabs Anticalins Pieris AG DARPins Molecular Partners Nanobodies* Ablynx Affimers Avacta Nucleic acid (DNA, RNA) and peptide (very small proteins) binding molecules have also been developed for some applications. Centyrins/Fynomers Janssen Affibodies Affibody Kunitz Domain Dyax Adnectins BMS 3 * NB: A Nanobody is a humanised llama antibody
4 Properties of a Good Binding Technology 4 Specificity (selectivity) binding the chosen target, or targets, with no off-target binding Binding affinity the strength with which the target is bound Immunogenicity therapeutic applications require the basic scaffold to have a low immunogenic response Stability to temperature, chemical conditions, biological environment Ease of modification addition of payloads such as drugs or fluorescent tags, attachment to multiple copies of itself or other proteins Ease of production good production yields with minimal purification requirements of the molecule itself and modified forms are required both in a manufacturing process and by a cell in vivo Rapid generation short time to create molecules that bind to a new target Small size allows deeper penetration of tissue and greater packing density on a surface Target space able to address a wide range of targets from proteins to small chemicals, toxic materials and targets that do not illicit an immune response in animals Clear IP ideally the technology should have clear unencumbered IP
5 Antibodies Antibodies are a well established and well understood technology Alternatives are not going to displace antibodies in applications where they work well Antibodies have significant limitations though: Specificity their specificity cannot be controlled if they are generated by immunisation of an animal such as a rabbit, sheep or mouse Stability they are quite stable molecules but many applications require conditions under which they are damaged or destroyed Modification methods to modify antibodies are well established but they are large and complex and controlling some modifications precisely is not straightforward Production antibodies are large and complex and manufacturing can be challenging and expensive; antibodies and antibody fragments chemical structure makes them more difficult for a cell to express Generation high quality antibodies take a long time (months to a year) to generate Size antibodies are very large which makes them less ideal for some applications e.g. solid tumor therapies Targets some targets cannot be hit using antibodies generated in animals because they do not illicit an immune response or are toxic for example IP the antibody IP landscape is complex: some key processes needed for antibody development and production require licenses and many applications have IP restrictions around the use of antibodies 5
6 Antibodies: Key Messages So, antibodies are great and where they work well they will remain the dominant technology But they have significant limitations which creates many valuable opportunities for alternatives 6
7 Nucleic Acid and Peptide Aptamers DNA (or RNA) and peptide aptamers are technologies that have been around for a long time Their advantage is that they are very simple and cheap to make and huge libraries of them can be generated which can be screened quickly to generate binders to new targets without relying on an immune response in animals There are a few examples of aptamer technologies working well in some applications But generally there are issues with: Specificity and affinity the small area of interaction with the target, and in the case of nucleic acids the limited number of chemical diversity, lead to difficulties in achieving the desired specificity and binding strength; target shape as well as chemistry may also present challenges for a small flexible aptamer that is relatively unconstrained Stability the resistance to chemical, thermal and biological degradation is a problem in may applications 7
8 Aptamers: Key Messages If aptamers worked well in a wide range of real-world applications (therapeutic and nontherapeutic) then they would have become widely adopted and there would be little interest in protein scaffolds or any other alternatives Aptamers have been developed by adding non-natural bases which mimic protein interactions more closely i.e. they have been made to look more protein scaffold-like Aptamers have had limited success despite many years of development but there are some areas in which they can excel 8
9 Protein Scaffolds Protein scaffolds are small proteins that present peptide loops (mimicking the binding loops of an antibody) to bind a target Protein scaffolds have the general benefit of being small and generated rapidly in the lab (which allows specificity to be controlled). Over the past twenty years or so many protein scaffolds have been developed in academia and most of these have disappeared or are of limited use because of poor performance in one way or another Issues with affinity, stability, immunogenicity and production have meant that interesting academic science has not cut it in real-world applications There are around ten protein scaffolds currently in existence that appear to work well in the real-world; all have either been acquired by pharma or developed by biotechs for therapeutics 9
10 Examples of Successful Protein Scaffolds Anticalins Pieris AG DARPins Molecular Partners Nanobodies Ablynx Affimers Avacta Centyrins/Fynomers Janssen Affibodies Affibody Kunitz Domain Dyax Adnectins BMS 10
11 Protein Scaffolds Most protein scaffolds are addressing the therapeutic market because this offers the greatest potential rewards Avacta is exploiting Affimers both as a therapeutic platform and as research/diagnostic reagents In the research and diagnostic reagents market the only competition is antibodies The Company has made clear its strategy in the non-therapeutic market: Avacta is addressing those applications where antibodies struggle and not trying to displace well established antibody products The Affimer technology s principal benefits which differentiate it from antibodies in a range of applications in this market are high specificity, stability, ease of modification, ease of production and hitting targets that are difficult or impossible for antibodies So, let s focus on how Affimer technology is differentiated from antibodies and other scaffolds as a therapeutic platform 11
12 Differentiated Affimer Medicines The Company believes, based on our own data, third party data in the public domain and our knowledge of antibodies and other scaffold technologies, that Affimers have competitive advantages in two key areas: 1 Ease of creating and manufacturing 2 multimers, flexible formatting Small size, stability and ease of expression in cells These advantages permit differentiated medicines for immuno-oncology to be developed in the following areas: 1 2 T-cell recruitment: multi-targeting to improve specificity and reduce tumour escape Agonism: multimers required Drug conjugates (solvent stability) Gene delivery (ease of expression) CAR-T (ease of expression of multimers) 12
13 Avacta s Immuno-oncology Strategy Based on the technical advantages that differentiate Affimer technology, we are focusing on T-cell recruitment and agonists in-house and collaborating with others to demonstrate the potential in gene delivery, CAR-T and drug conjugates T-cell recruiters In-house programme: Key Strength: Ease of multimerisation to create multi-targeting constructs T-cell A A A A Key Strength: Ease of multimerisation to generate agonists Collaboration with: Memorial Sloan Kettering Cancer Centre In-house programme: A Key Strength: Ease of expression to generate multiple CAR targeting B C B Tumor Gene Therapy/Intra-tumoral Delivery Collaboration with: Key Strength: Ease of 13 CAR-T Combination Therapies and Agonists expression and intracellular stability Drug Conjugates Key Strengths: Small size and solvent stability Collaboration with:
14 Protein Scaffolds: Key Messages There are a sufficient number of disease areas and treatment modalities, as well as potential pharma partners, for there to be space for several successful protein scaffolds Ablynx, Molecular Partners and Pieris (as well a several scaffolds acquired by large pharma) are in clinical stages of development Avacta has rapidly developed, and begun to commercialise, the Affimer protein scaffold since it acquired the patents to this technology in 2012 Affimer technology is clearly differentiated from antibodies in many non-therapeutic applications by its high specificity, stability, ease of modification, ease of production and hitting targets that are difficult or impossible for antibodies Affimer technology is differentiated as a therapeutic platform from antibodies, and is competitive with and may outperform the leading scaffolds because Affimer multimers can be easily manufactured and because Affimer proteins are stable and easily expressed by cells In the coming few years these technical benefits should translate into clinical progress (first in human), generation of valuable therapeutic assets and licensing/co-development agreements 14
15 Download the technical note: Affimer non-antibody Binders for Affinity Applications: Introduction and Key Feature Comparison here: goo.gl/v9wz3e
Custom Antibodies & Recombinant Proteins
Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely
More informationMeet the CEO developing the Next Generation of Antibody Therapeutics
Meet the CEO developing the Next Generation of Antibody Therapeutics Written by Evelyn Warner Editor in Chief, Labiotech.eu Crescendo Biologics has positioned itself as the successor of Cambridge Antibody
More informationAffimer Biotherapeutics: The preclinical development and validation of a PD-L1 antagonist in mouse
Affimer Biotherapeutics: The preclinical development and validation of a PD-L1 antagonist in mouse NGPT San Diego, 6 th June 2017 Amrik Basran Chief Scientific Officer Avacta Life Sciences Avacta Life
More informationAdvanced Therapeutic Antibody Discovery with Multiplexed Screening
Advanced Therapeutic Antibody Discovery with Multiplexed Screening White Paper Scientists need powerful tools that can deliver results to fully understand the ability of candidate antibodies to interrupt
More informationPartnered Discovery of High-Quality Antibody Drug Candidates. Company Presentation
Partnered Discovery of High-Quality Antibody Drug Candidates Company Presentation AbCheck s Unique Offering A unique source of human antibodies with one of the industry's most versatile technology platforms
More informationPartnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION DECEMBER 2016
Partnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION DECEMBER 2016 Corporate Overview A unique source of therapeutic human antibodies with one of the industry's most versatile
More informationAvacta Group plc. 4 October
Stock Data Share Price: 23.5p Market Cap: 27.1m Shares in issue: 115.5m Company Profile Sector: Ticker: Exchange: Healthcare AVCT AIM Activities Avacta is a biotechnology company which has developed the
More informationPartnered Discovery of High-quality Antibody Drug Candidates
Partnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION SEPTEMBER 2017 Corporate Overview A unique source of therapeutic human antibodies with one of the industry's most versatile
More information5/15/13. Agenda. Agenda. Introduction practical assignment: Identification of VHH against ErbB1/ EGFR. Structure of heavy chain antibodies
Introduction practical assignment: Identification of VHH against ErbB1/ EGFR Erik Hofman, Alex Klarenbeek, Rachid El Khoulathi 15-05-2013 Structure of heavy chain antibodies C H 1 C L V H V L V HH C H
More informationThink Aptamer! for therapeutics, diagnostics & analysis. Marine Laville, CEO Jean-Jacques Toulmé, CSO. Think Aptamer
Roadshow Cancer, Poitiers, March 27, 2018! for therapeutics, diagnostics & analysis. Marine Laville, CEO Jean-Jacques Toulmé, CSO I. Lebars Kissing TAR-R06 Bordeaux, France - Think aptamer! Alternative
More informationCustom Antibody Services. Antibodies Designed Just for You. HuCAL Recombinant Monoclonal Antibody Generation Service
Custom Antibody Services Antibodies Designed Just for You HuCAL Recombinant Monoclonal Antibody Generation Service Antibodies Designed Just for You What if there was a technology that would allow you to
More informationDiscovery on Target. Short Course Preview Deck
Discovery on Target Short Course Preview Deck Targeting of GPCRs with Monoclonal Antibodies Barbara Swanson, Ph.D. Sorrento Therapeutics, Inc. October 2014 GPCR Short Course Overview Introductions Brief
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationPersonalized CAR-T Immunotherapy Platform
GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom
More informationYour Antibody Source. prosci-inc.com. Extensive Antibody Services Broad Antibody Catalog
Your Source prosci-inc.com Extensive Services Broad Catalog Company Overview Established in 1998, ProSci Incorporated is a leading provider of high performance antibodies and custom antibody services.
More informationDevelopment of differentiated immuno-oncology therapeutics by using multivalent Nanobodies
Nanobodies Innovative therapeutics Development of differentiated immuno-oncology therapeutics by using multivalent Nanobodies Immune Checkpoint Inhibitors Europe Sandra Li - 17 November 2016 Forward looking
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationWhat is an Aptamer? smallest unit of repeating structure
What is an Aptamer? apto: mer: to fit smallest unit of repeating structure Aptamers are single stranded folded oligonucleotides that bind to molecular (protein) targets with high affinity and specificity
More informationHORIZON DISCOVERY Joint Venture between Horizon Discovery & Centauri Therapeutics
HORIZON DISCOVERY Joint Venture between Horizon Discovery & Centauri Therapeutics Briefing 2 nd March 2016 Exec Summary Horizon Discovery Group plc Enters Immuno-Oncology Therapeutic Development and Forms
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationApproaches to Nanoparticle Targeting. Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology
Approaches to Nanoparticle Targeting Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology Principles of drug targeting Drug targeting is the systemic or local administration
More informationGlobal Leader in Viral Vector Technologies
Global Leader in Viral Vector Technologies Gene Therapy Vaccines - Discovery 1 SIRION BIOTECH ANY GENE TO ANY CELL Expert for viral vectors Competitive proprietary viral vector platforms High-end enabling
More informationA New Peptide Drug Modality; Helix-Loop-Helix Technology. Interprotein Corporation
A New Peptide Drug Modality; Helix-Loop-Helix Technology Interprotein Corporation 1 Interprotein Corporation Location: Osaka, Japan Year Established: 2001 CEO & President: Masato Hosoda www.interprotein.com
More informationApplying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting Applying Affimers With an increasing number of antibody-based therapeutics entering the clinic, the need for validated anti-idiotypic
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationCellular Assays. A Strategic Market Analysis. Sample Slides
A Strategic Market Analysis Sample Slides 2002 For information contact: Frontline Strategic Consulting, Inc. 1065 E. Hillsdale Blvd, Suite 403, Foster City, CA 94404 650-525-1500 x125, x135 or x145 info@frontlinesmc.com
More informationImmunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN
Immunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN Immunotechnology a department at Lund University exploiting advanced technologies in biomedicine Genomics Antibody technology
More informationProteoGenix. Life Sciences Services and Products. From gene to biotherapeutics Target Validation to Lead optimisation
ProteoGenix Life Sciences Services and Products From gene to biotherapeutics Target Validation to Lead optimisation ProteoGenix Philippe FUNFROCK, founder and CEO French company located in Strasbourg,
More informationProgram overview. SciLifeLab - a short introduction. Advanced Light Microscopy. Affinity Proteomics. Bioinformatics.
Open House Program SciLifeLab Open House in Stockholm November 4, 2015 09:00-16:00 Contact: events@scilifelab.se Program overview 09:00-09:30-10:00-10:30-11:00-11:30-12:00-12:30-13:00-13:30-14:00-14:30-15:00-15:30-09:30
More informationCareer Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
More informationOncology Product and Platform Partnering Opportunity
Protein Medicinal Chemistry with an Expanded Genetic Code Oncology Product and Platform Partnering Opportunity April 2017 Ambrx has Made Advances in Proprietary Platform and Titer while Achieving Clinical
More informationIntroduction practical assignment: Identification of VHH/nanobodies against ErbB1/EGFR
Introduction practical assignment: Identification of VHH/nanobodies against ErbB1/EGFR Sofia Doulkeridou, Rachid El Khoulati, Paul van Bergen en Henegouwen 12-05-2014 Agenda Introduction to Nanobodies
More informationChemical Biology In-class discussion: Tethering
In-class discussion: Tethering This discussion will focus on various Tethering Methods described by workers at Sunesis (for a review, see Erlanson et al. Ann. Rev. Biophys. Biomol. Str. 2004). Regarding
More informationExpressive. Bacterial surface display for the identification of active ingredients for the pharmaceutical and cosmetics industry
Active Ingredient Research Expressive Bacterial surface display for the identification of active ingredients for the pharmaceutical and cosmetics industry Prof. Dr. Joachim Jose, Institute of Pharmaceutical
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): Modulating immune checkpoint pathways like CTLA-4 and PD-1 for cancer immunotherapy has gained much attention in recent years due to their immense
More informationFusion Antibodies. Genes to Proteins to Antibodies
Fusion Antibodies Genes to Proteins to Antibodies Why Fusion Antibodies? 12 years experience of Antibody drug development Milestoned Payments European based limited company High Quality outcomes for the
More informationImaging not only apoptosis. 30 October 2018 AusBiotech Australia Biotech Invest & Partnering 2018 Dr Barbara Meurer Chief Executive Officer
Imaging not only apoptosis. 30 October 2018 AusBiotech Australia Biotech Invest & Partnering 2018 Dr Barbara Meurer Chief Executive Officer 1 The company and a strong IP position Melbourne based biotech
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationModule I: Introduction Lecture 1 4 February, 2010
Module I: Introduction 20.109 Lecture 1 4 February, 2010 Introduction to: Module Overview Fundamental concepts and techniques in molecular biology A powerful and accessible strategy (SELEX) for identifying
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationRXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationNanoAssemblr Benchtop. Develop Future Nanomedicines
NanoAssemblr Benchtop Develop Future Nanomedicines Develop the Future of Medicine Overcome key challenges in advancing nanomedicines: Challenges with conventional production methods Solutions with the
More informationNanobodies against difficult targets Tackling ion channels
Nanobodies against difficult targets Tackling ion channels Collaborations in Ion Channel Drug Discovery 19-20 th June 2014 Nanobodies - Inspired by nature Company highlights Corporate Drug discovery and
More informationGenes to Proteins to Antibodies
Genes to Proteins to Antibodies About Us Fusion Antibodies is a CRO established in 2001 as a spin-out from Queen s University Belfast. The company building is situated in a charming area of Springbank
More informationAccelerating Takeda s R&D Success
Accelerating Takeda s R&D Success Our Mission is to Serve Patients We do more than develop medicines We innovate to improve patients lives Takeda R&D places the patient at the center of everything we do
More informationUNIVERSITY OF ROME LA SAPIENZA NANOTECHNOLOGIES ENGINEERING NANOPARTICLES IN BIOMEDICINE
UNIVERSITY OF ROME LA SAPIENZA NANOTECHNOLOGIES ENGINEERING NANOPARTICLES IN BIOMEDICINE Challenges The challenges are: in-situ analysis and in vivo at micro level recognize biomolecules functionality
More informationCelaSYS Customized PEGylation Solutions BOS CMC Copenhagen c e l a r e s gmbh Slide 1
CelaSYS Customized PEGylation Solutions BOS CMC Copenhagen 2012 c e l a r e s gmbh Slide 1 Overview Established in 2003 100% privately owned > 10 years of experience in PEGylation 18 employees, 7 with
More informationProteomics and Protein Microarrays
Introduction to BioMEMS & Medical Microdevices Proteomics and Protein Microarrays Companion lecture to the textbook: Fundamentals of BioMEMS and Medical Microdevices, by Prof., http://saliterman.umn.edu/
More informationNSE Grantees Meeting December 2015
NSE Grantees Meeting December 2015 The Spherical Nucleic Acid (SNA) Nanoparticle Changes the Paradigm for Oligo Therapeutics Linear DNA SNA Each company limited by chemistry, modality, and tissue of interest
More informationThe DIG System. Labeling and Detection of Nucleic Acids
The DG System Labeling and Detection of Nucleic Acids The DG System Specifically Label and Detect Nucleic Acids Publishable results require high level specific detection and low background. Do your hybridizations
More informationCombination Therapies. Inhibitors
Combination Therapies with Immune The Value of Partnerships Checkpoint - Case Study - Inhibitors The Value of Partnerships - Case Study - New data is forecasting that the immune checkpoint inhibitor market
More informationPersonalized Healthcare Diagnostik und Therapie aus einer Hand
Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position
More informationModule I: Introduction
Module I: Introduction 20.109 Lecture 1 3 February, 2011 Introduction to: Module Overview Fundamental concepts and techniques in molecular biology Appreciating nucleic acids (RNA in particular) as more
More informationTHE CRISPR-CAS9 DISPUTE
WHO OWNS THE INTELLECTUAL PROPERTY? THE CRISPR-CAS9 DISPUTE UTRF Tech Talks Dr. Lakita Cavin February 23, 2017 WHAT IS CRISPR-Cas9 Clustered Regularly-Interspaced Short Palindromic Repeats/CRISPR associated
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationVision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University
Vision, aims and strategies Department of Immunology, Genetics and Pathology Uppsala University April19,2011 SCOPEOFACTIVITIESATIGP Research at the Department focuses on translational medicine through
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationSolutions for Your Research
Solutions for Your Research Custom Antibody Services Polyclonal Monoclonal The service we offer is very complete starting from rabbits, mice and rats. The different formats provided by Primm depend on
More informationThe Two-Hybrid System
Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine The Two-Hybrid System Carolina Vollert & Peter Uetz Institut für Genetik Forschungszentrum Karlsruhe PO Box 3640 D-76021 Karlsruhe
More informationELONA: the evolution of ELISA Banushan Balansethupathy, Andrew Brentnall Aptamer Group Ltd
ELONA: the evolution of ELISA Banushan Balansethupathy, Andrew Brentnall Aptamer Group Ltd Enzyme-linked immunosorbent assay (ELISA) was developed for the detection and quantification of proteins, peptides
More informationBiosimilars China Guideline. Dr Dr Michel Mikhail
Biosimilars China Guideline Dr Dr Michel Mikhail 1 Contents Regulatory context of biologicals in China Decree 28 issued by SFDA October 2007 Proposed biosimilars guideline 10/29/14 Reference drugs to use
More informationModule Overview. Lecture. DNA library synthesis (PCR) Introduction
Module Overview Day 1 Lecture Introduction Lab DNA library synthesis (PCR) 2 3 4 5 6 7 8 SELEX I: Building a Library SELEX II: Selecting RNA with target functionality SELEX III: Library deconvolution,
More informationMarina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics
Marina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics CAMBRIDGE, MA, August 14, 2013 Marina Biotech, Inc. (OTC Pink: MRNA): Assigns Unlocked Nucleobase
More informationUpdate on the new immunogenicity guideline in the EU
Update on the new immunogenicity guideline in the EU draft 2016 EBF, Lisbon 27 th September 2016 Venke Skibeli, Senior Scientist, PhD Norwegian Medicines Agency, Member of the CHMP - BMWP, EMA, London
More informationAccessible answers. Targeted sequencing: accelerating and amplifying answers for oncology research
Accessible answers Targeted sequencing: accelerating and amplifying answers for oncology research Help advance precision medicine Accelerate results with Ion Torrent NGS Life without cancer. This is our
More informationNGEx. High quality sequential extraction of both DNA and RNA from the same tissue specimen. Fast.
NGEx Next Generation Extraction technology The only TRULY fully automated extraction solution. No manual reagent handling. No split samples: Sequential extraction of both DNA and RNA in a single workflow
More informationExpressed genes profiling (Microarrays) Overview Of Gene Expression Control Profiling Of Expressed Genes
Expressed genes profiling (Microarrays) Overview Of Gene Expression Control Profiling Of Expressed Genes Genes can be regulated at many levels Usually, gene regulation, are referring to transcriptional
More informationSISSA Scuola Internazionale Superiore di Studi Avanzati
SISSA Scuola Internazionale Superiore di Studi Avanzati Prof. Ing. Gianluigi Rozza SISSA Director s Delegate, Prof. Stefano Ruffo «Salute 4.0 e l innovazione che parla italiano» Riunione degli Addetti
More informationModule Overview. Lecture
Module Overview Day 1 2 3 4 5 6 7 8 Lecture Introduction SELEX I: Building a Library SELEX II: Selecting RNA with target functionality SELEX III: Technical advances & problem-solving Characterizing aptamers
More informationDIANA assay for in vitro diagnostics Overview and collaboration proposal
DIANA assay for in vitro diagnostics Overview and collaboration proposal Institute of Organic Chemistry and Biochemistry AS CR, Prague, Czech Republic DNA-linked Inhibitor ANtibody Assay What is DIANA
More informationNew Product: X-Aptamer Selection Kit. Updated April 2015
New Product: X-Aptamer Selection Kit Updated April 2015 Technology Basics X-Aptamers are synthetic affinity molecules Similar in function to monoclonal antibodies X-Aptamers combine a variety of chemical
More informationIMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS
IMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS As scientists gain an advanced understanding of diseases at the molecular level, the biopharmaceutical industry
More informationTREE CODE PRODUCT BROCHURE
TREE CODE PRODUCT BROCHURE Single Molecule, Real-Time (SMRT) Sequencing technology offers: Long read sequencing ~10 Gb with 20 kb average read lengths for WGS ~20 Gb with 40 kb average read length for
More informationDNA. Clinical Trials. Research RNA. Custom. Reports CLIA CAP GCP. Tumor Genomic Profiling Services for Clinical Trials
Tumor Genomic Profiling Services for Clinical Trials Custom Reports DNA RNA Focused Gene Sets Clinical Trials Accuracy and Content Enhanced NGS Sequencing Extended Panel, Exomes, Transcriptomes Research
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established
More informationCOPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES
COPE CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES FAQs This brochure addresses FAQ and is prepared solely for the German market. Local adjustments may be necessary. Please contact us if you require additional
More informationGenome Editing Inventive Energy
Genome Editing Inventive Energy Top 10 Patent Classes Genome Editing Inventive Energy JUNE 2018 Crafitti Consulting Pvt Ltd www.crafitti.com 1 GENOME EDITING INVENTIVE ENERGY 2018 INTERNATIONAL PATENT
More informationChapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More information1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationTranslational Research
Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationTechnology Transfer, Academic and Industry Cooperations
Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and
More informationDharmacon TM solutions for studying gene function
GE Healthcare Capabilities Overview Dharmacon TM solutions for studying gene function RNAi Gene Expression Gene Editing RNA Interference Our RNAi products encompass the most complete portfolio of innovative
More informationIntroduction to IMI. Pierre Meulien Executive Director Innovative Medicines Initiative
Introduction to IMI Pierre Meulien Executive Director Innovative Medicines Initiative What is the Innovative Medicines Initiative? EU funding goes to: - universities - SMEs - patient groups etc 2.5 bn
More informationMICROARRAYS: CHIPPING AWAY AT THE MYSTERIES OF SCIENCE AND MEDICINE
MICROARRAYS: CHIPPING AWAY AT THE MYSTERIES OF SCIENCE AND MEDICINE National Center for Biotechnology Information With only a few exceptions, every
More informationPerform reproducible immunoprecipitation in less than 40 minutes
Perform reproducible immunoprecipitation in less than 40 minutes Dynabeads products Immunoprecipitation made easy with low nonspecific binding, high yield, and reproducibility Magnetic beads have become
More informationHealthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation
Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)
More informationCONCEPT OF SIMILAR MEDICINAL PRODUCT IN THE CONTEXT OF THE ORPHAN LEGISLATION: ADAPTATION TO TECHNICAL PROGRESS
Ref. Ares(2016)6257284-04/11/2016 04 November 2016 Submission of comments on the Consultation Document CONCEPT OF SIMILAR MEDICINAL PRODUCT IN THE CONTEXT OF THE ORPHAN LEGISLATION: ADAPTATION TO TECHNICAL
More informationCurrent Experience in Immunogenicity Assessment of next Generation Biologics- Nanobodies
Current Experience in Immunogenicity Assessment of next Generation Biologics- Nanobodies European Immunogenicity Symposium Veerle Snoeck Nanobodies - Inspired by nature Ablynx NV Outline! Introduction!
More informationNaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER
Nanoplasmid TM Platform NaNoplasmid TM The Nanoplasmid is a dramatically improved Key Cassette (
More informationChallenges in receptor occupancy determination assays by flow cytometry in drug development
Challenges in receptor occupancy determination assays by flow cytometry in drug development DATE 17 November 2016 PRESENTED BY Martine Broekema, Ph.D. Associated Director of Bioanalytical Sciences Large
More informationCancer Research. Peptide Innovations in. Neo-Epitope Analysis Immunotherapy Cancer Proteomics Enzyme Profiling Epigenetics
Peptide Innovations in Cancer Research Neo-Epitope Analysis Immunotherapy Cancer Proteomics Enzyme Profiling Epigenetics Innovative Peptide Solutions Neo-Epitope Analysis Neo-epitopes encoded by the mutanome
More informationBEH.462/3.962J Molecular Principles of Biomaterials Spring 2003
Lecture 17: Drug targeting Last time: Today: Intracellular drug delivery Drug targeting Reading: T.J. Wickham, Ligand-directed targeting of genes to the site of disease, Nat. Med. 9(1) 135-139 (2003) Drug
More informationImmunological Applications. Chapter 8: Background
Immunological Applications Chapter 8: Background The Immune System Types of Immunity Innate The natural immunity present at birth Acquired A specific response to foreign substances. Some cells remember
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationBridging the Gap Between Basic and Clinical Research. Julio E. Celis Danish Cancer Society
Bridging the Gap Between Basic and Clinical Research Julio E. Celis Danish Cancer Society Barriers and Oportunities in Translational Research Promise of the new technologies What is Europe doing? Challenges
More informationCancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development
Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development Phil L Huillier Director Cancer Research Technology Ltd London, UK Who we are Cancer Research
More information